

Curriculum Vitae

Branimir I. (Brandy) Sikic, M.D.

PERSONAL DATA:

Date of Birth: October 18, 1947
Place of Birth: Graz, Austria
Citizenship: U. S. A., naturalized 1962
Marital Status: Married, three children

EDUCATION AND TRAINING:

1968 B. S. (Biology, Fine Arts), Georgetown University, Washington, DC
1972 M. D., University of Chicago School of Medicine, Chicago, IL
1972-75 Intern and Resident in Internal Medicine, Georgetown University Hospital
1975-77 Research Associate, Drug Interactions Section (Dr. Ted Gram), Developmental Therapeutics Program, National Cancer Institute, NIH, Bethesda, MD
1978-79 Medical Oncology Clinical Fellow, Georgetown University Hospital

ACADEMIC APPOINTMENTS:

1977-78 Investigator, Drug Interactions Section, Developmental Therapeutics Program, National Cancer Institute, NIH, Bethesda, MD
1979-86 Assistant Professor of Medicine (Oncology and Clinical Pharmacology), Stanford University School of Medicine, Stanford, CA
1986-87 Visiting Scientist, Molecular Biology Laboratory (Dr. George Stark), Imperial Cancer Research Fund, London, England,
1986-96 Associate Professor of Medicine (Oncology and Clinical Pharmacology), Stanford University School of Medicine
1992-93 Associate Program Director, General Clinical Research Center, Stanford University School of Medicine and Stanford University Hospital
1993-2008 Program Director, General Clinical Research Center, Stanford University School of Medicine and Stanford University Hospital
1997-present Professor of Medicine (Oncology and Clinical Pharmacology), Stanford University School of Medicine
1998-2004 Director, Cancer Clinical Trials Office, Stanford University Medical Center
2008 - Co-Director, Stanford University Center for Clinical and Translational Education and Research (Spectrum)
2008 - Director, Clinical and Translational Research Unit, Stanford University Center for Clinical and Translational Education and Research (Spectrum)
2009-present Associate Director for Clinical Research, Stanford Cancer Center

MILITARY SERVICE:

Commissioned Corps, United States Public Health Service (USPHS), Surgeon-04, 1975-78
Inactive Reserve Officer, Surgeon-04, USPHS, 1978-1990

HONORS:

Presidential Medal for Science and Medicine, Order of the Morning Star Katarina Zrinska, Government of Croatia, 2010

(HONORS, cont.):

Statesman Award, American Society of Clinical Oncology (ASCO), 2010
Best Doctors in America, 2002-10
John H. Blaffer Visiting Professor, M. D. Anderson Cancer Center, 2003
Oncology Teaching Award, Stanford University School of Medicine, 2000
Plenary Lecturer, Netherlands Cancer Institute Symposium, Amsterdam, 1999
Plenary Lecturer, Federation of European Biology Societies (FEBS) Course on ABC Transporters, Gösau, Austria, 1997
70th Anniversary of the CRC Lecturer, British Association of Cancer Research, London, 1993
Pfizer Visiting Professor in Clinical Pharmacology, Dartmouth Medical School, 1992
Warren J. Schneider Memorial Lecturer, University of the Pacific, 1990
Faculty Development Award in Clinical Pharmacology, Pharmaceutical Manufacturers Association Foundation, 1981-83

PROFESSIONAL SOCIETY MEMBERSHIPS:

American College of Physicians
American Association for Cancer Research
American Society of Clinical Oncology
American Society of Hematology
American Federation for Clinical Research
Cancer Molecular Therapeutics Research Association
Western Society for Clinical Investigation
Western Association of Physicians

CERTIFICATIONS AND LICENSURE:

Diplomate, National Board of Medical Examiners, 1973
Diplomate, American Board of Internal Medicine, 1975
Diplomate, Medical Oncology, American Board of Internal Medicine, 1979, recertified 2010
Medical License, State of California, 1979-present

ACTIVE GRANT SUPPORT:

NIH R01 CA 114037, "Taxane Resistance in Breast and Ovarian Cancer Cells." Principal Investigator, 8/1/2007 - 4/30/2012.
NIH UL1 RR 025744, "Stanford Center for Clinical and Translational Education and Research (SCCTER)." CTSA Award, Co-Principal Investigator, 05/19/2008 - 04/30/2013.
NIH P30 CA124435, Cancer Center Support Grant. Associate Director for Clinical Research of the Cancer Center, 06/04/07-05/31/15.
Exelixis, Inc., "A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors." Principal Investigator, 07/01/2010-06/30/2012.
Johnson & Johnson, "CCL2 Blockade as a Therapy in Ovarian Cancers." Principal Investigator, 08/01/2010-7/31/2013.
Basilea Pharmaceutica International Ltd., "Determinants of Sensitivity and Resistance to Basilea Pharmaceutics International Ltd. Investigational Compound BAL27862." Principal Investigator, 09/01/2010-08/31/2011.

Hoffmann-La Roche, Inc./Genentech, Inc./Plexxikon, Inc., "Protocol NP25163: A Phase I, randomized, open-label, multi-center, multiple dose study to investigate the pharmacokinetics and pharmacodynamics of RO5185426 administered as 240 mg tablets to previously treated BRAF V600E positive metastatic melanoma patients." Principal Investigator, 9/1/2010-8/31/2012.

Genentech, Inc., "A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects with Solid Tumors – MEK4592g." Principal Investigator, 05/15/08-03/31/11.

Human Genome Sciences, Inc., "A Phase I, dose escalation study to evaluate the safety and tolerability of AEG40826.2HC1 in patients with advanced solid tumors." Principal Investigator, 05/30/2008 - 05/29/2011.

OncoMed Pharmaceuticals, Inc., "A Phase I, Dose Escalation Study of OMP-21M18 in Subjects with Solid Tumors." Principal Investigator, 02/06/09 – 03/31/11.

Amgen, Inc., "A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors." Principal Investigator, 10/27/09 – 09/30/13.

PAST GRANT SUPPORT (partial listing):

NIH R01 CA 92474, "Regulation of the Human *MDR1* Gene." Principal Investigator, 04/01/2002 – 03/31/2007.

NIH R01 CA 90916, "Genomic Profiling of Childhood De Novo and Relapsed AML." Co-Investigator (G. Dahl, P. I.), 04/01/2001 – 03/31/2007.

NIH R33 CA 89830, "Gene Expression Profiling of Unknown Primary Cancers." Principal Investigator, 04/01/2001 – 03/31/2006.

NIH R01 CA 52168, "Modulation of Multidrug Resistance Mechanisms." Principal Investigator, 06/01/1990 – 05/31/2003.

NIH M01 RR-00070, "General Clinical Research Center." Program Director, 12/01/1992 - 05/31/08.

NIH R01 CA 68217, "Tubulin Genes and Drug Resistance." Principal Investigator, 05/01/1996 – 05/31/2000.

NIH R01 CA 42417, "Morpholino Anthracyclines." Principal Investigator, 08/01/1986 – 07/31/1989.

NIH R01 CA 33303, "Cellular Pharmacology of Anthracyclines in Human Cancers." Principal Investigator, 07/01/1982 – 06/30/1985.

Department of Defense DAMD17-03-1-0239, "Mechanisms of Taxane Resistance in Ovarian Carcinomas." Principal Investigator, 04/01/2003 – 03/31/2007.

Department of Defense DAMD17-94-J-4352, "Paclitaxel (Taxol) Resistance in Breast Cancer Cells." Principal Investigator, 10/01/1994 – 09/30/1998.

American Cancer Society RPG-88-005-11-CDD, "Multidrug Resistance in Human Cancer Cells." Principal Investigator, 07/01/1997 - 06/30/2001.

American Cancer Society DHP-76, "Multidrug Resistance in Human Cancer Cells." Principal Investigator, 07/01/1993 - 06/30/1997.

American Cancer Society CH-411, "Multidrug Resistance in Human Cancer Cells." Principal Investigator, 01/01/1988 - 06/30/1993.

American Cancer Society CH-323, "Multidrug Resistance in Human Cancer Cells." Principal Investigator, 01/01/1985 - 06/30/1993.

California Cancer Research Program, State of California, "Genomic Profiling of Ovarian Cancer." Principal Investigator, 01/01/1999 – 12/31/2001.

- AstraZeneca, Inc., "A Phase I Trial of ZD6474 [Vandetanib] Combined with Capecitabine and Oxaliplatin (XELOX) and Bevacizumab for the First-Line Treatment of Metastatic Colorectal Cancer." Principal Investigator, 07/06/2006 – 06/30/2010.
- Bristol-Myers Squibb Inc., "Determinants of Response to Microtubule Stabilizing Drugs." Principal Investigator, 07/01/2007 – 12/31/2008.
- Bristol-Myers Squibb, Inc., "A Phase I Study of Ixabepilone Administered as 3 Oral Doses Each Separated by 6 Hours Every 21 Days in Subjects with Advanced Cancer." Principal Investigator, 05/15/08 – 07/15/09.
- Sanofi-Aventis, Inc., "Mechanisms of Resistance to XRP6258 and XRP9881 in Breast and Ovarian Cancer Cell Lines." Principal Investigator, 06/01/06 – 05/31/08.
- Rhone-Poulenc Rorer Pharmaceuticals, Inc., "Taxotere Resistance in Human Breast and Ovarian Cancers." Principal Investigator, 01/01/1999 – 12/31/2000.
- Basilea Pharmaceutica AG, "Sensitivity of Basilea Pharmaceutica Investigational Compound BAL27862 in MDR1/ABCB1(-) Taxane-Resistant Human Breast and Ovarian Cell Models." Principal Investigator, 01/01/2009 - 09/30/2009.
- Symphony Evolution, Inc., "XL647-002: A Phase I Dose-escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally daily to Subjects with Solid Tumors." Principal Investigator, 07/25/2006 - 8/31/2010.
- Exelixis Pharmaceuticals, Inc., "A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL518 Administered Orally Daily to Subjects with Solid Tumors." Principal Investigator, 07/12/2007 - 07/11/2009.
- Exelixis Pharmaceuticals, Inc., "A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally to Subjects with Solid Tumors." Principal Investigator, 05/11/2004 - 04/18/2007
- Human Genome Sciences, Inc., "A Phase I, Multi-center, Phase I Trial of HGS-ETR2 (Fully-Human Monoclonal Antibody to the Trail-R2) in Subjects with Advanced Solid Malignancies." Principal Investigator, 02/26/2004 - 02/25/2007.
- Human Genome Sciences, Inc., "A Multi-Center, Phase I Trial of HGS-ETR2 (HGS1018, a Fully Human Monoclonal Antibody to TRAIL-R2) in Combination with Gemcitabine, Pemetrexed, Doxorubicin, or Folfiri In Subjects with Solid Malignancies." Principal Investigator, 03/29/06 - 2003/31/2008.
- Isis Pharmaceuticals, Inc., "Phase I/II Trials of an Antisense Inhibitor of PKC-a." Principal Investigator, 08/01/1997 - 07/31/2000.
- Lilly Research Laboratories, Inc., "A Phase 1 Dose Escalating Study of LY335979 in Combination with Mitoxantrone in Patients with Hormone-Refractory Prostate Cancer." Principal Investigator, 11/01/98 – 04/30/2000.
- Bristol-Myers Squibb, Inc., "Phase I Study of BMS-310705 Given Every Three Weeks in Patients with Advanced Solid Malignancies," Principal Investigator, 03/01/02 - 12/31/03.
- Bristol-Myers Squibb, Inc., "Phase I Study of BMS-188797 Administered on Day 1 and Day 8 Every 21 Days in Patients with Advanced Solid Malignancies," Principal Investigator, 03/01/00 - 12/31/01.
- Sandoz, Inc., "A Phase II Study of Paclitaxel and PSC 833 in Metastatic Colorectal Carcinoma," Principal Investigator, 06/01/96 - 05/31/98.

PATENTS:

- United States Patent #5,830,697; Issued Nov. 3, 1998, "P-Glycoprotein Mutant Resistant to Cyclosporin Modulation"
- United States Patent #7,875,274; Issued January 25, 2011, "Protein Modulators of Resistance to Alkylating Agents"

UNIVERSITY AND HOSPITAL COMMITTEES:

Executive Committee, Stanford Center for Clinical and Translational Education and Research (SPECTRUM), 2008-present
Advisory Committee, Clinical and Translational Research Unit, Stanford University School of Medicine, 2008-present
Research Space Planning Committee, Stanford Department of Medicine, 2008-09
Nephrology Faculty Search Committee, Stanford Department of Medicine, 2007-08
Scientific Review Committee, Stanford Cancer Center, 2007-present (ex officio)
Clinical Research Planning Committee, Department of Medicine, 2004-06
Chair, Research Policy Review Committee for HIPAA, Stanford University School of Medicine, 2002-03
Translational Research Planning Committee for the School of Medicine, 2002-2005
Oncology Informatics Steering Committee, Stanford University School of Medicine, 2002-5
Appointments and Promotions Committee, Department of Medicine, Stanford University School of Medicine, 1999-2003
Steering Committee, Clinical Cancer Center, Stanford University Medical Center, 1998-2004
General Clinical Research Center Advisory Committee, Stanford University School of Medicine, 1992-2008 (ex officio)
Admissions Committee, Stanford University Program in Cancer Biology, 1997-2001
Dean's Executive Subcommittee for the Development of a Gene Therapy Program, Stanford University School of Medicine, 1995
Admissions Committee, Stanford University School of Medicine, 1989-92
Chair, Quality of Care Committee, Medical Service, Stanford Univ. Hospital, 1982-84
Compromised Host Committee, Stanford University Hospital, 1982-86

PEER REVIEW AND NIH ADVISORY ACTIVITIES:

Marsha Rivkin Center for Ovarian Cancer Research, Pilot Study Award Program and Scientific Scholar Award Program Review Committee, 2010-present
Member, Translational and Clinical Review Committee, Cancer Prevention and Research Institute of Texas (CPRIT), 2009-present
Chair, NIH Review Committee for Regional Translational Research Centers, 2005
Chair, NIH Scientific Review Group, Experimental Therapeutics I Study Section, 2000-02
Co-chair, Developmental Therapeutics Section, Progress Review Group in Gynecologic Cancers, National Cancer Institute (NCI), 2000-02
Chair, Drug Resistance Session, Gastric Cancer State of the Science Workshop, NCI, 2001
Member, NIH Scientific Review Group, Experimental Therapeutics I Study Section, 1997-2000
Chair, NIH Scientific Review Committee, Phase I Trials of Anticancer Agents, 1997
American Cancer Society, Scientific Advisory Committee on Drug Development, Hematology, and Pathology, 1991-1996 (Vice-chair, 1995; Chair, 1996)
NIH Scientific Review Group, Gene Therapy of Cancer, 1992
NIH Scientific Review Group, Outstanding Investigator Grant Program, 1984-1990
NIH Representative, U. S. - Japan Agreement, Anticancer Drug Development, 1985, '90, '94
American Cancer Society Institutional Research Grant Review Committee, 1984-86
Scientific Review Board, Margaret E. Early Medical Research Trust, 1983-present
NIH Scientific Review Group, Clinical Development of Anticancer Agents, 1984, 1997
NIH Scientific Review Group, Human Tumor Stem Cell Cloning Assay, 1982

PROFESSIONAL SOCIETY COMMITTEES AND SYMPOSIA:

Board of Directors, Cancer Molecular Therapeutics Research Association, 2010-present
Member, Medical Oncology Subspecialty Board Examining Committee, American Board of Internal Medicine (ABIM), 2007-present
Member, Oncology Examining Committee, American College of Physicians MKSAP VII. Recertifying Course and Examination, 1983-85
Program Committee, American Society of Hematology, 2000

American Association for Cancer Research (AACR):

Gertrude B. Elion Cancer Research Award Scientific Review Committee, 2010
Co-chair, Pharmacology, AACR Annual Meeting Program Committee, 2008-09
Chair, Major Symposium on "Resistance to Targeted Therapies," AACR Annual Meeting, 2009
Chair, AACR Forum, "Antisense: the Clinical Perspective," 2003 AACR Annual Meeting
Co-chair, AACR Minisymposium, "Mechanisms and Modulation of Drug Resistance," 2003
Co-chair, AACR Minisymposium, "Transporters and Drug Resistance," 2002
Chair, Education Committee, AACR, 1999-2000
Program Committee, AACR, 1995, 2001, 2002

American Society of Clinical Oncology (ASCO):

ASCO Translational Research Professorship Review Committee, 2007
Chair, Best of ASCO Committee, American Society of Clinical Oncology (ASCO), 2006-07
Chair, Scientific Program Committee, ASCO, 2005-6
Member, ASCO Multidisciplinary Cancer Management Course Working Group, 2003-06
International Affairs Committee, ASCO, 2003-06
Awards Committee, ASCO, 1993-97 (Chair 1995-6)
Co-chair, ASCO Integrated Symposium, "New Agents and New Targets," 2002
Communications Committee, ASCO, 2000-03
Program Committee, ASCO annual meeting, 1983, 1984, 1986, 1993, 2000, 2001 (Chair, Subcommittee on Clinical Pharmacology, 1993, 2001)

EDITORIAL BOARDS:

Associate Editor, *Journal of Experimental Therapeutics and Oncology*, 1995-present
Associate Editor, *Advances in Oncology*, 1992-2001
Associate Editor, *American Journal of Medicine*, 1998-99
Editorial Board, *Investigational New Drugs*, 2004-present
Editorial Board, *Molecular Cancer Therapeutics*, 2001-05
Editorial Board, *The Oncologist*, 1995-2000
Editorial Board, *Cancer Therapeutics*, 1997-99

COOPERATIVE CLINICAL TRIALS GROUP PARTICIPATION:

Chair, Pharmacology Committee, Eastern Cooperative Oncology Group (ECOG), 1992-2003
Leukemia Committee, ECOG, 1991-2003
Laboratory Science Committee, ECOG, 1990-2003
New Agents and Pilot Studies Committee (ECOG), 1990-92
Chair, Chemotherapy and Drug Development Committee, Northern California Oncology Group (NCOG), 1987-1990
Chair, Gynecologic Cancer Committee, NCOG, 1985-86
Chair, Lung Cancer Committee, NCOG, 1983-85

NATIONAL AND INTERNATIONAL CONTINUING EDUCATION ACTIVITIES:

- Advisor on Cancer Policy, Ministry of Health and Ministry of Science, Education and Sport, Republic of Croatia, 2007-2009
- Co-chair, Molecular Therapeutics of Cancer Conference (formerly the Gordon Conference on Cancer Therapeutics), Stanford University, 2009
- Chair, "Multidisciplinary Management of Cancers: a Case-Based Approach," sponsored by Stanford University School of Medicine, 2007-09
- Chair, Northern California Tumor Board at Silverado, 2001-06
- Chair and Founder, Central European Oncology Congress, "Advances in Cancer Detection and Treatment," Opatija, Croatia, 1998, 2000, 2002, 2004, 2007, 2009, 2011
- Chair, First and Second UCSF Stanford Tumor Boards at Silverado, "A Multidisciplinary Approach to Cancer Treatment," Napa, CA, 1999 and 2000
- Chair, Symposium on "Current Treatment and Future Directions in the Management of Lung Cancer and Non-Hodgkin's Lymphoma," San Francisco, CA, 1997
- Co-chair, International Conference on Bleomycin Chemotherapy, San Francisco, CA, 1984

STANFORD UNIVERSITY TEACHING:

Stanford Undergraduate Honors Thesis Advisor

Course Lecturer:

- Pharmacology 201, 202
- Cancer Biology 243, "The Molecular and Cellular Biology of Cancer"
- Oncology Fellows and Radiotherapy Residents lecture series
- Human Biology 154, "Biosocial Aspects of Cancer," for undergraduates
- Human Biology 111 / Biology 112, "Human Physiology" for undergraduates
- Cultural Anthropology 174: "Cultures of Disease: Cancer"

ADVISORY BOARDS AND DATA SAFETY MONITORING COMMITTEES:

- Scientific Advisor, Rudjer Boskovic Institute, Zagreb, Croatia, 2009-present
- Data Monitoring Committee, Protocol #A6181087, Pfizer, Inc., 2007-2010
- Data and Safety Monitoring Committee, California Cancer Consortium, 2007-present
- Colorectal Cancer Advisory Board (Chair), Astrazeneca Corporation, 2006
- Scientific Advisory Board (Chair), Kanisa Pharmaceuticals, 2004-2009
- Clinical Advisory Board, Sunesis Pharmaceuticals, 2003-2007
- Oncology Advisory Board, Johnson and Johnson, 2003-present
- Oncology Advisory Board, Exelixis, Inc., 2002-06
- Oncology Advisory Board, Eli Lilly, Inc., 2002-03
- Oncology Advisory Board, Celera, Inc., 2001-03
- Oncology Advisory Board (Chair), Axys Pharmaceuticals, Inc., 1999-2001
- Scientific Advisory Board (Chair) Ontogen Corporation, 1998-2002
- Scientific Advisory Board, Rigel Pharmaceuticals, Inc., 1997-99
- Scientific Advisory Board, Pharmacyclics, Inc., 1996-2001 and 2009-present
- Oncology Advisory Board, Isis Pharmaceuticals, Inc., 1996-2001
- Oncology Advisory Board, Glaxo-Wellcome Corporation, 1995-99
- Scientific Advisor, Pfeiffer Medical Research Foundation, 1995-2002
- Scientific Advisor, Margaret E. Early Trust, 1995-present
- Oncology Advisory Board, Novartis (Sandoz) Pharmaceuticals, 1992-99
- Oncology Advisory Board, Bristol-Myers Squibb Company, 1982-2004

RESEARCH INTERESTS:

The clinical and pre-clinical pharmacology of antineoplastic drugs:

Mechanisms of anti-cancer drug action and resistance

Multidrug resistance genes

Tubulin targeted agents

Anticancer drug discovery and development

Gene expression profiling to define prognostic factors and determinants of therapeutic response:

Current and recent projects include studies of unknown primary cancers, colorectal carcinomas, ovarian and breast cancers, glioblastomas, and acute myeloid leukemias

Phase I trials of new anticancer agents and combinations:

Current agents in Phase I trials include the multitargeted tyrosine kinase inhibitors XL-647 and XL-184, the MEK inhibitor XL-518, the IAP inhibitor AEG40826, the Notch ligand antibody OMP 21M18, and the mutant B-RAF inhibitor PLX4032

Clinical Trials of Therapeutic Biomarkers for Personalized Medicine

ADDRESSES: Oncology Division, CCSR North 1105
Stanford University Medical Center
Stanford, CA 94305-5151
Tel. (650) 725-6427,
FAX: (650) 736-1454
E-mail: brandy@stanford.edu

Web site: http://med.stanford.edu/labs/branimir_sikic/

BIBLIOGRAPHY:**Peer Reviewed Articles:**

1. Sikic BI, Walker RD and Peterson DR: An evaluation of a program for the treatment of alcoholism in Croatia. *Alcoholism* 1: 109-20, 1972. Also in: *Int. J. Soc. Psych.* 171-82, 1972.
2. Renault PF, Schuster CR, Freedman DX, Sikic BI, Mello D and Halaris A: Repeat administration of marihuana smoke to humans. *Arch. Gen. Psych.* 31: 95-102, 1974.
3. Sikic BI and Baumel IP: The interaction of flurazepam with diphenylhydantoin in rats. *Drug Metab. Dispos.* 4: 584-586, 1976.
4. Sikic BI, Mimnaugh EG, Litterst CL and Gram TE: The effects of ascorbic acid deficiency and repletion on pulmonary, renal, and hepatic drug metabolism in the guinea pig. *Arch. Biochem. Biophys.* 179: 663-671, 1977.
5. Sikic BI, Mimnaugh EG and Gram TE: Effects of dietary ascorbic acid supplementation on hepatic drug-metabolizing enzymes in the guinea pig. *Biochem. Pharmacol.* 26:2037-41, 1977.
6. Sikic BI, Young DM, Mimnaugh EG and Gram TE: Quantification of bleomycin pulmonary toxicity in mice by changes in lung hydroxyproline content and morphometric histopathology. *Cancer Res.* 38: 787-792, 1978.
7. Mimnaugh EG, Waring RW, Sikic BI, Magin RL, Drew R, Litterst CL, Gram TE, and Guarino AM: The effect of whole body hyperthermia on the disposition and metabolism of adriamycin in rabbits. *Cancer Res.* 38: 1420-1425, 1978.
8. Sikic BI, Collins JM, Mimnaugh EG and Gram TE: Improved therapeutic index of bleomycin when administered by continuous infusion in mice. *Cancer Treat. Rep.* 62: 2011-2017, 1978.
9. Litterst CL, Sikic BI, Mimnaugh EG, Guarino AM and Gram TE: In vitro drug metabolism in male and female athymic, nude mice. *Life Sci.* 22: 1723-1730, 1978.
10. Mimnaugh EG, Siddik ZH, Drew R, Sikic BI and Gram TE: The effects of alpha-tocopherol on the toxicity, disposition, and metabolism of adriamycin in mice. *Toxicol. Appl. Pharmacol.* 49: 119-126, 1979.
11. Magin RL, Sikic BI and Cysyk RL: Enhancement of bleomycin activity against Lewis lung tumors in mice by local hyperthermia. *Cancer Res.* 39: 3792-3795, 1979.
12. Siddik ZH, Sikic BI, Drew R, Mimnaugh EG, Litterst CL and Gram TE: Lack of correlation between cortisol-induced precocious maturation of the fetal rabbit lung and drug metabolism. *Biochem. Pharmacol.* 28: 683-685, 1979.
13. Drew R, Sikic BI, Mimnaugh EG, Litterst CL and Gram TE: The distribution of ¹⁴C-imipramine in mice bearing Lewis lung carcinoma. *Life Sci.* 25: 1813-1820, 1979.
14. Sikic BI, Siddik ZH and Gram TE: Relative pulmonary toxicity and antitumor effects of two new bleomycin analogues, pepleomycin and tallysomycin A. *Cancer Treat. Rep.* 64: 659-667, 1980.
15. Siddik ZH, Drew R, Litterst CL, Mimnaugh EG, Sikic BI and Gram TE: Hepatic cytochrome P-450-dependent metabolism and enzymatic conjugation of foreign compounds in vitamin A deficient rats. *Pharmacology* 21: 383-390, 1980.
16. Rahman A, Kessler A, More N, Sikic B, Rowden G, Woolley P and Schein PS: Liposomal protection of adriamycin-induced cardiotoxicity in mice. *Cancer Res.* 40: 1532-1537, 1980.
17. Gullo JJ, Litterst CL, Maguire PJ, Sikic BI, Hoth DF and Woolley PV: Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. *Cancer Chemother. Pharmacol.* 5: 21-26, 1980.
18. Ahlgren JD, Smith FP, Kerwin DM, Sikic BI, Weiner JH and Schein PS: Pulmonary disease as a complication of chlorozotocin chemotherapy. *Cancer Treat. Rep.* 65: 223-229, 1981.

19. MacKintosh FR, Evans TL and Sikic BI: Methodologic problems in clonogenic assays of spontaneous human tumors. *Cancer Chemother. Pharmacol.* 6: 205-210, 1981.
20. Litterst CL, Torres IJ, Arnold S, McGunagle D, Furner R, Sikic BI and Guarino AM: Absorption of antineoplastic drugs following large-volume intraperitoneal administration to rats. *Cancer Treat. Rep.* 66: 147-155, 1982.
21. Chak LY, Daniels JR, Sikic BI, Torti FM, Lockbaum P and Carter SK: Patterns of failure in small cell carcinoma of the lung. *Cancer* 50: 1857-1863, 1982.
22. Harker WG, MacKintosh FR, and Sikic BI: Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. *Cancer Res.* 43: 4943-4950, 1983.
23. Chak LY, Paryani SB, Sikic BI, Lockbaum P, Torti FM and Carter SK: Diagnostic accuracies of clinical studies in patients with small cell carcinoma of the lung. *J. Clin. Oncol.* 1: 290-294, 1983.
24. Carlson RW, Sikic BI, Turbow MM and Ballon SC: Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary. *J. Clin. Oncol.* 1: 645-651, 1983.
25. Chak LY, Sikic BI, Tucker MA, Horns RC, and Cox RS: Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung. *J. Clin. Oncol.* 2: 385-390, 1984.
26. Ballon SC, Portnuff JC, Sikic BI, Turbow MM, Teng NNH and Soriero OM: Second-look laparotomy in epithelial ovarian carcinoma: precise definition, sensitivity, and specificity of the operative procedure. *Gynecol. Oncol.* 17: 154-160, 1984.
27. Daniels JR, Chak LY, Sikic BI, Lockbaum P, Kohler M, Carter SK, Reynolds R, Bohnen R, Gandara D, and Yu J: Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. *J. Clin. Onc.* 2: 1192-1199, 1984.
28. Turbow MM, Ballon S, Sikic BI, and Koretz M: Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial carcinoma. *Cancer Treatment Rep.* 69: 465-467, 1985.
29. Picozzi VJ, Sikic BI, Carlson RW, Koretz M, and Ballon SB: Bleomycin, mitomycin, and cisplatin therapy for advanced squamous carcinoma of the uterine cervix: a phase II study of the Northern California Oncology Group. *Cancer Treat. Rep.* 69: 903-905, 1985.
30. Weber S, Zuckerman JE, Bostwick DG, Bensch KG, Sikic, BI and Raffin TA: Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro. *J. Clin. Investig.* 75: 306-309, 1985.
31. Sikic BI, Ehsan MN, Harker WG, Friend NF, Brown BW, Newman RA, Fagan MA, and Acton EM: Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog. *Science, (Wash., D. C.)* 228: 1544-1546, 1985.
32. Levin VA, Byrd D, Sikic BI, Etiz BB, Campbell J, Borcich JK, and Davis RL: Central nervous system toxicity and cerebrospinal fluid pharmacokinetics of intraventricularly administered bleomycin in beagles. *Cancer Res.* 45: 3810-3815, 1985.
33. Harker WG, and Sikic BI: Multidrug (Pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line, MES-SA. *Cancer Res.* 45: 4091-4096, 1985.
34. Chak LY, Zatz LM, Wasserstein P, Cox RS, Kushlan PD, Porzig KJ, and Sikic BI: Neurologic dysfunction in patients treated for small cell carcinoma of the lung: a clinical and radiological study. *Int. J. Radiation Oncol. Biol. Physics.* 12: 385-389, 1986.
35. Zuckerman JE, Raffin TA, Brown JM, Newman RA, Etiz BB, and Sikic BI: In vitro selection and characterization of a bleomycin-resistant subline of B16 melanoma. *Cancer Res.* 46: 1748-1753, 1986.

36. Harker WG, Bauer D, Etiz BB, Newman RA, and Sikic BI: Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. *Cancer Res.* 46: 2369-2373, 1986.
37. Schray MF, Martinez A, Howes AE, Ballon SC, Podratz KC, Sikic BI, and Malkasian GD: Advanced epithelial ovarian cancer: toxicity of whole abdominal irradiation after operation, combination chemotherapy, and re-operation. *Gynecol. Oncol.* 24: 68-80, 1986.
38. Langlotz CP, Fagan LM, Tu SW, Sikic BI, and Shortliffe EH: Combining artificial intelligence and decision analysis for automated therapy planning assistance. In: *MEDINFO 86*, Salamon R, Blum B, and Jorgensen M (Eds.) Elsevier Science Publishers, North Holland, 1986, pp. 794-798.
39. Sikic BI, Scudder SA, Ballon SC, Soriero OM, Christman JE, Suey L, Ehsan MN, Brandt AE, and Evans TL: High dose megestrol acetate therapy of ovarian carcinoma: A phase II study of the Northern California Oncology Group. *Sem. Oncol.* 13: (Suppl. 4) 26-32, 1986.
40. DeGregorio MW, Lum BL, Holleran WM, Wilbur BJ, and Sikic BI: Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Cancer Program. *Cancer Chemother. Pharmacol.* 18: 235-238, 1986.
41. Yamauchi T, Raffin TR, Yang P, and Sikic BI: Differential protective effects of varying degrees of hypoxia on the cytotoxicities of etoposide and bleomycin. *Cancer Chemother. Pharmacol.* 19: 282-286, 1987.
42. Langlotz CP, Fagan LM, Tu SW, Sikic BI, and Shortliffe EH: A therapy planning architecture that combines decision theory and artificial intelligence techniques. *Computers and Biomedical Res.* 20: 279-303, 1987.
43. Berinstein N, Matthey KK, Papahadjopoulos D, Levy R, and Sikic BI: Antibody-directed targeting of liposomes to human cell lines: role of binding and internalization on growth inhibition. *Cancer Res.* 47: 5954-5959, 1987.
44. Coleman CN, Carlson RW, Halsey J, Kohler M, Gribble M, Sikic BI, and Jacobs C: Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole. *Cancer Res.* 48: 3528-3532, 1988.
45. Uemura M, Winant RC, Sikic BI, and Brandt AE: Characterization and immunoassay of human tumor-associated galactosyltransferase isoenzyme II. *Cancer Res.* 48: 5325-34, 1988.
46. Beckman RA, McFall PJ, Sikic BI, and Smith SD: Doxorubicin and the alkylating anthracycline MRA-CN: comparative in vitro potency against leukemic and bone marrow cells. *J. Natl. Cancer Inst.* 80: 361-365, 1988.
47. Shray MF, Martinez A, Howes AE, Podratz KC, Ballon SC, Malkasian GD, and Sikic BI: Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy. *J. Clin. Oncol.* 6: 1433-9, 1988.
48. Scudder SA, Brown JM, and Sikic BI: DNA cross-linking and cytotoxicity of the alkylating anthracycline cyanomorpholino-doxorubicin (MRA-CN) in multidrug resistant cells. *J. Natl. Cancer Inst.* 80: 1294-1298, 1988.
49. Lau DHM, Lewis AL, and Sikic BI: Association of DNA cross-linking with potentiation of the morpholino derivative of doxorubicin by human liver microsomes. *J. Natl. Cancer Inst.* 81: 1034-1038, 1989.
50. Parce JW, Owicki JC, Kercso KM, Sigal GB, Wada HG, Muir VC, Bousse LJ, Ross KL, Sikic BI, and McConnell HM: Detection of cell-affecting agents with a silicon biosensor. *Science (Wash., D. C.)* 246: 243-247, 1989.
51. Gosland MP, Lum BL, and Sikic BI: Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. *Cancer Res.*, 49: 6901-6905, 1989.

52. Lau DHM, Ross KL, and Sikic BI: Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin, MRA-CN. *Cancer Res.* 50: 4056-4060, 1990.
53. John M, Flam M, Sikic B, Rotman M, Cooper J, Phillips T, Malec M, Hannigan J, and Phillips T: Preliminary results of concurrent radiotherapy and chemotherapy in advanced cervical carcinoma: a phase I-II prospective intergroup NCOG-RTOG study. *Gynecol. Oncol.* 37: 1-5, 1990.
54. Christman JE, and Sikic BI: Delivery of a normal infant following cisplatin, vinblastine, and bleomycin (PVB) chemotherapy for malignant teratoma of the ovary during pregnancy. *Gynecol. Oncol.* 37: 292-295, 1990.
55. Carlson RW, Dorfman RF, and Sikic BI: Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy. *Cancer* 66: 2092-2094, 1990.
56. Aihara M, Sikic BI, Blume KG, and Chao NJ: Assessment of purging with multidrug-resistance (MDR) modulators and VP-16: results of long-term marrow culture. *Exp. Hematol.* 18: 940-944, 1990.
57. Berry JM, Jacobs C, Sikic B, Halsey J, and Borch RF: Modification of cisplatin toxicity with diethyldithiocarbamate. *J. Clin. Oncol.* 8: 1585-1590, 1990.
58. Chao NJ, Aihara M, Blume KG, and Sikic BI: Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow. *Exp. Hematol.* 18: 1193-1198, 1990.
59. Aihara M, Aihara Y, Schmidt-Wolf G, Schmidt-Wolf I, Sikic BI, Blume KG, and Chao NJ: A combined approach for purging multidrug resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy. *Blood* 77: 2079-2084, 1991.
60. Carlson RW, Sikic BI, Gandara, DR, Hendrickson CG, Wittlinger PS, Shields JA, Wong PP, White JE, Meakin CJ, McWhirter KM, Lamborn KR, and Phillips TL: Late consolidative radiotherapy in the treatment of limited-stage small cell lung cancer. *Cancer* 68: 948-958, 1991.
61. Marie JP, Zittoun R, and Sikic BI: Multidrug resistance (*mdr1*) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. *Blood* 78: 586-592, 1991.
62. Lau DHM, Lewis AD, Ehsan MN, and Sikic BI: Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. *Cancer Res.* 51: 5181-5187, 1991.
63. Jacobs C, Kaubisch S, Halsey J, Lum BL, Gosland M, Coleman CN, and Sikic BI: The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. *Cancer* 67: 1518-24, 1991.
64. Marie JP, Brophy NB, Ehsan MN, Aihara Y, Mohamed NA, Cornbleet J, Chao NJ, and Sikic BI: Expression of multidrug resistance gene *mdr1* mRNA in a subset of normal bone marrow cells. *Br. J. Haematol.* 81: 145-152, 1992.
65. Lewis AD, Duran GE, Lau DHM, and Sikic BI: Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism. *Int. J. Radiation Oncol. Biol. Physics*, 22: 821-4, 1992.
66. Lau DHM, Duran GE, and Sikic BI: Characterization of the covalent DNA binding of the morpholino and cyanomorpholino derivatives of doxorubicin. *J. Natl. Cancer Inst.* 84: 1587-1592, 1992.
67. Lewis AD, Lau DHM, Duran GE, Wolf CR, and Sikic BI: Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. *Cancer Res.* 52: 4379-4384, 1992.

68. Kühl JS, Sikic BI, Blume KG, and Chao NJ: Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model. *Exp. Hematol.* 20: 1048-1054, 1992.
69. Yahanda AM, Adler KM, Fisher G, Brophy NA, Hardy R, Halsey J, Gosland MP, Lum BL, and Sikic BI: A phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. *J. Clin. Oncol.* 10: 1624-1634, 1992.
70. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Halsey J, Gosland MP, and Sikic BI: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial of modulation of multidrug resistance. *J. Clin. Oncol.* 10: 1635-1642, 1992.
71. Kühl J-S, Durán GE, Chao NJ, and Sikic BI: Effects of the methoxymorpholino derivative of doxorubicin and its bioactivated form versus doxorubicin on human leukemia and lymphoma cell lines and normal bone marrow. *Cancer Chemother. Pharmacol.* 33: 10-16, 1993.
72. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, and Sikic BI: Clinical trials of modulation of multidrug resistance: pharmacokinetic and pharmacodynamic considerations. *Cancer* 72: 3502-3514, 1993.
73. Brophy NA, Marie J-P, Rojas VA, Warnke RA, McFall PJ, Smith SD, and Sikic BI: *Mdr1* gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques. *Leukemia* 8: 327-335, 1994.
74. Jaffrézou J-P, Sikic BI, and Laurent G: Cyclosporin A and cyclosporin SDZ PSC 833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cells. *Blood* 83: 482-489, 1994.
75. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, and Sikic BI: A phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. *J. Clin. Oncol.* 12: 835-842, 1994.
76. Jaffrézou J-P, Chen G, Durán GE, Kühl J-S, and Sikic BI: Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. *J. Natl. Cancer Inst.* 86: 1152-1158, 1994.
77. Lau DHM, Duran GE, Lewis AD, and Sikic BI: Metabolic conversion of methoxy-morpholinyl doxorubicin: from a DNA strand-breaker to a DNA cross-linker. *Br. J. Cancer* 70: 79-84, 1994.
78. Chen G, Jaffrezou J-P, Fleming WH, Duran GE, and Sikic BI: Prevalence of multidrug resistance related to activation of the *mdr1* gene in human sarcoma mutants derived by single-step doxorubicin selection. *Cancer Res.* 54: 4980-4988, 1994.
79. Dong Y-j, Chen G, Duran GE, Kouyama K, Chao AC, Sikic BI, Gollapudi SV, Gupta S, and Gardner P: Volume-activated chloride current is not related to P-glycoprotein overexpression. *Cancer Res.* 54: 5029-5032, 1994.
80. Lau DHM, Duran GE, and Sikic BI: Analysis of intracellular retention of morpholinyl anthracyclines in multidrug resistant cells by interactive laser cytometry. *Int. J. Oncology* 5: 1273-1277, 1994.
81. Muller C, Goubin F, Ferrandis E, Cornil-Schwartz I, Bailly JD, Bordier C, Benard J, Sikic BI, and Laurent G: Evidence for transcriptional control of human *mdr1* gene expression by verapamil in multidrug-resistant leukemic cells. *Mol. Pharmacol.* 47: 51-56, 1995.
82. Cufer T, Vrhovec I, Skrk J, Pfeifer M, Pajk B, Zakotnik B, Filipic B, Rode B, and Sikic BI: Cyclosporine A increases serum cortisol levels in rabbits. *Anti-Cancer Drugs* 6: 615-618, 1995
83. Marie J-P, Simonin G, Legrand O, Delmer A, Faussat A-M, Lewis AD, Sikic BI, and Zittoun R: Glutathione-S transferases π , and μ and *mdr1* mRNA expression in normal lymphocytes and chronic lymphocytic leukaemia. *Leukemia* 9: 1742-1747, 1995.
84. Jaffrezou J-P, Chen G, Duran G, Muller C, Bordier C, Laurent G, Sikic BI, and Levade T: Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. *Biochim Biophys Acta* 1266: 1-8, 1995.

85. Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, and Sikic BI: Decreased mutation rate for doxorubicin resistance and suppression of *mdr1* gene activation by PSC 833. *J. Natl. Cancer Inst.* 87: 1593-1602, 1995.
86. Jaffrezou J-P, Dumontet C, Derry WB, Duran G, Chen G, Tsuchiya E, Wilson L, Jordan MA, and Sikic BI: Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. *Oncology Res.* 7: 517-527, 1995.
87. McCauley DL, Lum BL, and Sikic BI: Effect of different mathematical methods on etoposide area under the curve values and pharmacodynamic response predictions. *Cancer Chemother. Pharmacol.* 37: 286-288, 1996.
88. Luckie DB, Krouse ME, Law TC, Sikic BI, and Wine JJ: Doxorubicin selection for MDR1/P-glycoprotein reduces swelling-activated K⁺ and Cl⁻ currents in MES-SA cells. *Am. J. Physiol.* 270 (*Cell Physiol.* 39): C1029-C1036, 1996.
89. Duran GE, Lau DHM, Lewis AD, Kühl J-S, Bämmler TK, and Sikic BI: Differential single-versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues. *Cancer Chemother. Pharmacol.* 38: 210-216, 1996.
90. Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, and Sikic BI: Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). *Cancer Res.* 56: 1091-1097, 1996.
91. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dietel M, Fojo AJ, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Leith CP, Lehnert M, Paietta E, Pavelic ZP, Rimzsa L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, and Weinstein R: Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. *Cancer Res.* 56: 3010-3020, 1996.
92. Dumontet C, Duran GE, Steger KA, Murphy G, Sussman H, and Sikic BI: Differential expression of tubulin isotypes during the cell cycle. *Cell Motility Cytoskel.*, 35: 49-58, 1996.
93. Kühl J-S, Krajewski S, Duran GE, Reed JC, and Sikic BI: A spontaneously resistant variant of murine P388 leukemia with broad cross-resistance to cytotoxins and overexpression of the long form of the Bcl-X protein. *Br. J. Cancer* 75: 268-274, 1996.
94. Chen G, Durán GE, Steger KA, Lacayo NJ, Jaffrézou JP, Dumontet C, and Sikic BI: Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. *J. Biol. Chem.* 272: 5974-5982, 1997.
95. Sikic BI, Fisher GA, Lum, BL, Halsey J, Beketic-Oreskovic L, and Chen G: Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. *Cancer Chemother. Pharmacol.* 40 (Suppl): S13-S19, 1997.
96. Advani R, Warnke R, Sikic BI, and Horning S: Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. *Ann. Oncol.* 8: 601-603, 1997.
97. Lum BL, Lane KJ, Synold TW, Goram A, Charnick SB, and Sikic BI: Validation of a limited sampling model for etoposide area under the curve determinations. *Pharmacotherapy* 17: 887-890, 1997.
98. Cufer T, Vrhovec I, Pfeifer M, Skrk J, Borstnar S, and Sikic BI: Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits. *Cancer Chemother. Pharmacol.* 41: 517-521, 1998.
99. Washington CB, Duran GE, Man MC, Sikic BI, and Blaschke TF: Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* 19: 203-209, 1998.

100. Tallman MS, Lee S, Sikic BI, Paietta E, Bennett JM, Rowe JM, and Wiernik PH: Mitoxantrone, etoposide, and cytarabine plus cyclosporine in patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Group pilot study. *Cancer* 85: 358-367, 1999.
101. Sikic BI: Author update. (Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Halsey J, Gosland MP, and Sikic BI: Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial of modulation of multidrug resistance. *J. Clin. Oncol.* 10: 1635-1642, 1992). *Classic Papers and Current Comments: Highlights of Cancer Pharmacology Research*, 4: 140-147, 1999.
102. Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, and Greenberg PL: Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (valsopodar). *Blood* 93: 787-795, 1999.
103. Yuen AR, Halsey J, Fisher GA, Geary RS, Macias D, Holmlund JT, Dorr A, and Sikic BI: Phase I study of antisense oligonucleotide to protein kinase C- α (Isis 3521/CGP64128A) in patients with cancer. *Clin Cancer Res* 5: 3357-3363, 1999.
104. Lum BL, Kaubisch S, Fisher GA, Brown BW, and Sikic BI: Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (*MDR1* gene) mediated drug resistance. *Cancer Chemother Pharmacol* 45: 305-311, 2000.
105. Dahl GV, Lacayo NJ, Brophy N, Dunussi-Joannopoulos K, Weinstein HJ, Chang M, Sikic BI, and Arceci RJ: Mitoxantrone, etoposide, and cyclosporine (MEC) therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. *J Clin Oncol* 18: 1867-1875, 2000.
106. Chen GK, Lacayo NJ, Duran GE, Cohen D, and Sikic BI: Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted Phe³³⁵. *Mol Pharmacol*, 57: 769-777, 2000.
107. Yuen AR and Sikic BI: Clinical studies of antisense therapy in cancer. *Front. Biosci.* 5: D588-93, 2000. <http://www.bioscience.org/2000/v5/d/yuen/fulltext.htm>
108. Chen GK, Duran GE, Mangili A, Beketic-Oreskovic L, and Sikic BI: *MDR1* activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells. *Br J Cancer* 83: 892-898, 2000.
109. Cufer T, Pfeifer M, Vrhovec I, Frangez R, Kosec M, Mrhar A, Grabnar I, Golouh R, Vogric S, and Sikic BI: Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valsopodar and mitotane or doxorubicin. *Anticancer Drugs* 11: 303-309, 2000.
110. Leo C, Jang Y, Chan E, Padilla D, Huang BC, Lin T, Gururaja T, Hitoshi Y, Lorens JB, Anderson DC, Sikic B, Luo Y, Payan DG, Xu X, and Nolan GP: Dominant effector genetics in mammalian cells. *Nat Genet* 27: 23-29, 2001.
111. Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, and Sikic BI: A Phase I trial of doxorubicin, paclitaxel and valsopodar (PSC 833), a modulator of multidrug resistance. *Clin Cancer Res* 7: 1221-1229, 2001.
112. Miller RA, Woodburn KW, Fan Q, Lee I, Miles D, Duran G, Sikic BI, and Magda D: Motexafin gadolinium: a redox active drug that enhances the efficacy of bleomycin and doxorubicin. *Clin Cancer Res* 7: 3215-3221, 2001.
113. Sale S, Sung R, Shen P, Yu K, Wang Y, Duran GE, Kim J-H, Fojo T, Oefner P, and Sikic BI: Conservation of the class I beta tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel resistant ovarian cancers. *Mol Cancer Ther* 1: 215-225, 2002.
114. Chen GK, Lacayo NJ, Duran GE, Wang Y, Bangs CD, Rea S, Kovacs M, Cherry AM, Brown JM, and Sikic BI: Preferential expression of a mutant allele of the amplified *ABCB1* gene in drug-resistant variants of a human sarcoma. *Genes Chromosomes Cancer* 34: 372-383, 2002.

115. Lacayo NJ, Lum BL, Becton BL, Weinstein H, Ravindranath Y, Chang MN, Bomgaars L, Lauer SJ, Sikic BI and Dahl GV: Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. *Leukemia* 16: 920-927, 2002.
116. Sale S, Oefner PJ, and Sikic BI: Re: Genetic analysis of the β tubulin gene, TUBB, in non-small-cell lung cancer. *J Natl Cancer Inst* 94: 776-777, 2002.
117. Chin DL, Lum BL, and Sikic BI: Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by UV/visible HPLC. *J Chromatogr B* 779: 259-269, 2002.
118. Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O'Dwyer PJ, Fero MJ, Kristensen GB, Borresen-Dale AL, Hastie T, Tibshirani R, Van De Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, and Sikic BI: Gene expression patterns in ovarian carcinomas. *Mol Biol Cell*, 14: 4376-4386, 2003.
119. Advani R, Fisher GA, Lum BL, Jambalos C, Cho CD, Cohen M, Gollerkeri A, and Sikic BI: Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. *Clin Cancer Res*, 9: 5187-5194, 2003.
120. Lacayo NL, Duran GE, and Sikic BI: Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug resistant (MDR) cells. *J Exp Ther Oncol*, 3: 127-135, 2003.
121. Hartman, A-R, Grekowicz A, Lum BL, Carlson RW, Shurman C, Sikic BI, Shapiro R, and Stockdale FE: Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. *Breast Cancer Res Treatment*, 82: 61-69, 2003.
122. Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, and Sikic BI: A Phase II trial of aprinocarsen (Isis 3521, LY900003), an antisense oligonucleotide inhibitor of protein kinase C α administered as a 21-day infusion to patients with advanced ovarian cancer. *Cancer* 100: 321-326, 2004.
123. Chen GK, Sale S, Tan T, Ermoian RP, and Sikic BI: CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human *MDR1* gene by interaction with an inverted CCAAT box in human cancer cells. *Mol Pharmacol*, 65: 906-16, 2004.
124. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum BL, Chin DL, Dewald G, Paietta E, Bennett JM, and Rowe JM: Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a Phase III Trial (E2995). *J Clin Oncol*, 22: 1078-86, 2004.
125. Lacayo NL, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, and Dahl GV. Gene expression profiles at diagnosis in *de novo* childhood AML patients identify FLT3 mutations with good clinical outcomes. *Blood*, 104: 2646-54, 2004.
126. Tu IP, Schaner M, Diehn M, Sikic, BI, Brown PO, Botstein D, and Fero MJ. A method for detecting and correcting feature misidentification on expression microarrays. *BMS Genomics*, 5: 64, 2004.
127. Dumontet C, Jaffrezou JP, Tsuchiya E, Duran GE, Chen G, Derry WB, Wilson L, Jordan MA, and Sikic BI. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization. *Bull Cancer*, 91: E81-112, 2004.
128. Bredel M, Bredel C, Juric D, Kim Y, Vogel H, Garsh GR, Recht LD, Pollack JR, and Sikic BI. Amplification of whole tumor genomes from limited sources of fresh-frozen and paraffin-embedded DNA. *J Mol Diagn*, 7: 171-82, 2005.
129. Cho CD, Fisher GA, Halsey J, and Sikic BI. Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies *Investigational New Drugs*, 24: 117-23, 2006 [Epub ahead of print, July 18, 2005].

130. Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, and Sikic BI. A Phase II study of IFOX therapy (gefitinib, 5-fluorouracil, leucovorin, oxaliplatin) in previously treated patients with metastatic colorectal cancer. *J Clin Oncol*, 23: 5613-19, 2005.
131. Bredel M, Bredel C, Juric D, Garsh GR, Vogel H, Recht LD, and Sikic BI. High-resolution genome-wide mapping of genetic alterations in human glial brain tumors. *Cancer Res*, 65: 4088-96, 2005.
132. Chi KN, Chia SK, Dixon R, Newman MJ, Wachter VJ, Sikic BI, and Gelmon KA. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. *Investigational New Drugs*, 23: 311-315, 2005.
133. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, and Sikic BI: Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. *Cancer Res*, 65: 8679-89, 2005.
134. Advani R, Lum BL, Fisher GA, Halsey J, Chin DL, Jacobs CD, and Sikic BI: A Phase I trial of liposomal doxorubicin, paclitaxel, and valspodar (PSC-833), an inhibitor of multidrug resistance. *Ann Oncol*, 16: 1968-73, 2005 [Epub doi:10.1093/annonc/mdi396, August 26, 2005].
135. Chen GK, Wang YC, Schaner ME, Francisco B, Duran GE, Juric D, Huff LM, Padilla-Nash H, Ried T, Fojo T, and Sikic BI: Genetic and epigenetic modeling of the origins of multidrug resistant cells in a human sarcoma cell line. *Cancer Res*, 65: 9388-97, 2005.
136. Advani R, Lum B, Fisher G, Halsey J, Geary R, Holmlund J, Kwoh T, Dorr F, and Sikic B. A phase I trial of aprinocarsen (ISIS 3521 /LY900003), an antisense inhibitor of protein kinase C- α administered as a 24-hour weekly infusion schedule in patients with advanced cancer. *Investigational New Drugs*, 23: 467-477, 2005.
137. Juric D, Sale S, Hromas RA, Yu R, Wang U, Duran GE, Tibshirani R, Einhorn LH, and Sikic BI: Molecular characterization of germ cell tumors by microarray gene expression profiling. *PNAS*, 102: 17763-68, 2005 [Epub Nov 23, 2005].
138. Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Sikic BI, Arceci RJ, and Weinstein H. Randomized use of cyclosporine A (CSA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. *Blood*, 107: 1315-24, 2006[Epub ahead of print, Oct 27, 2005].
139. Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, and Sikic BI: Tumor necrosis factor- α -induced protein 3 as a putative regulator of nuclear factor- κ B-mediated resistance to O6-alkylating agents in human glioblastomas. *J Clin Oncol*, 24: 274-87, 2006 [Epub Dec 19, 2005].
140. Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK, Chen X, and Sikic BI: Regional activation of chromosome 7q with and without gene amplification in taxane-selected human ovarian carcinoma cell lines. *Genes Chromosomes Cancer*, 45: 365-74, 2006 [Epub ahead of print, Dec 28, 2005].
141. DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC, and Dahl GV: Low or absent SPARC expression in acute myeloid leukemia with *MLL* rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. *Leukemia*, 20: 426-32, 2006 [Epub ahead of print, Jan 19, 2006].
142. Carlson RW, O'Neill A, Goldstein L, Sikic BI, Abramson N, Steward JA, Davidson NE, and Wood, WC: A pilot Phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. *Cancer Investigation*, 24: 677-81, 2006.
143. Kuo T, Fisher GA, and Sikic BI: Targeting EGFR with the IFOX regimen (gefitinib, 5-fluorouracil, leucovorin, oxaliplatin) in patients with previously treated metastatic colorectal cancer. *Am J Oncol Rev*, 2006.

144. Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, Goldstone AH, O'Dwyer PJ, Paietta E, and Sikic BI: Differential gene expression patterns and interaction networks in BCR/ABL positive and negative adult acute lymphoblastic leukemias. *J Clin Oncol*, 25: 1341-9, 2007.
145. Juric D, Bredel C, Sikic BI, Bredel M: Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors. *Methods Mol Biol* 377: 187-202, 2007.
146. Chan JK, Ueda SM, Sugiyama V, Stave C, Shin JY, Monk BJ, Sikic BI, Osann K, and Kapp DS: An analysis of phase II biologic studies and subsequent phase III trials - what are the predictors for success? *J Clin Oncol*, 26: 1511-8, 2008. [Epub Feb 19, 2008].
147. Fisher GA, Kuo T, Ramsey M, Schwartz E, Rouse RV, Cho CD, Halsey J, and Sikic BI: A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin (IFOX) in Previously Untreated Patients with Metastatic Colorectal Cancer. *Clin Cancer Res* 14: 7074-9, 2008.
148. Marcelletti JF, Multani PS, Lancet JE, Baer MR, and Sikic BI: Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia. *Leukemia Res*, 33: 769-74, 2009 [Epub ahead of print, Oct 29, 2008].
149. Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, and Sikic BI: A Phase I Trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. *Leukemia Res*, 33: 1055-61, 2009 [Epub ahead of print, Dec 22, 2008].
150. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R, and Sikic BI: A network model of a cooperative genetic landscape in brain tumors. *JAMA*, 302: 261-75, 2009.
151. Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, Das S, Scheck AC, Kessler JA, Soares MB, Sikic BI, Harsh GR, and Bredel M: Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. *JAMA*, 302: 276-89, 2009.
152. Wakelee HA, Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, Ullrich SJ, Fisher GA, and Tolcher AW: Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. *Ann Oncol*, 21: 376-81, 2010 [Epub ahead of print, July 24, 2009].
153. O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Chin D, Buck S, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, and Dahl GV: Phase I study of valspodar (PSC 833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. *Pediatr Blood Cancer*, 54: 694-702, 2010.
154. Galatin, PS, Advani RH, Fisher GA, Francisco B, Julian T, Losa R, and Sikic BI: Phase I trial of oblimersen (Genasense) and gemcitabine in refractory and advanced malignancies. *Investigational New Drugs*, [Epub ahead of print, March 28, 2010] In press, 2010.
155. Spicakova T, O'Brien MM, Duran GE, Sweet-Cordero A, and Sikic BI: Expression and silencing of microtubule-associated protein Tau in breast cancer cells. *Mol Cancer Ther* 9: 2970-81, 2010 [Epub Nov 9, 2010].
156. Bredel M, Scholtens DM, Yadav AK, Alvarez A, Renfrow JJ, Chandler JP, Yu ILY, Carro MS, Dai F, Tagge MJ, Ferrarese R, Bredel C, Phillips HS, Lukac PJ, Robe PA, Weyerbrock A, Vogel H, Dubner S, Mobley B, He X, Scheck AC, Sikic BI, Aldape KD, Chakravarti A, Harsh GR: *NFKB1A* deletion in glioblastomas. *New Engl J Med* 364: 627-37, 2011 [Epub Dec 22, 2010].
157. Cabebe EC, Fisher GA, and Sikic BI: A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. *Investigational New Drugs* 2011, In press.

Review Articles and Book Chapters:

1. Gram TE, Sikic BI, Litterst CL and Mimnaugh EG: Differential influence of physiological, pharmacological, and pathological alterations on hepatic and extrahepatic drug metabolism. In: *Microsomes and Drug Oxidations*, Ullrich V, Roots I, Hildebrandt A, Estrabrook R and Conney AH (Eds.), Pergamon Press, New York, 1977, pp. 527-533.
2. Sikic BI, Mimnaugh EG and Gram TE: Development of quantifiable parameters of bleomycin toxicity in the mouse lung. In: *Bleomycin: Current Status and New Developments*, Carter SK, Crooke S and Umezawa H (Eds.), Academic Press, New York, 1978, pp. 293-7.
3. Gram TE, Sikic BI, Litterst CL, Mimnaugh EG, Drew R and Siddik Z: The role of the lung in the metabolism and disposition of xenobiotics. In: *Industrial and Environmental Xenobiotics*, Fouts JR and Gut I (Eds.), Excerpta Medica, Amsterdam, 1978, pp. 53-58.
4. Sikic BI: Methyltransferases and drug metabolism. In: *Extra-hepatic Metabolism of Drugs and Other Foreign Compounds*, Gram TE (Ed.), Spectrum Publications, Inc., New York, 1980, pp. 533-549.
5. Sikic BI, Daniels JR, Chak L, Alexander M, Kohler M, and Carter SK: POCC versus POCC/VAM chemotherapy for small cell anaplastic (oat cell) lung cancer. In: *Nitrosoureas: Current Status and New Developments*, Baker L, Carter SK and Schein PS (Eds.), Academic Press, New York, 1981, pp. 221-231.
6. Sikic BI: The rational basis for cancer chemotherapy. In: *Modern Pharmacology*, Craig R and Stitzell R (Eds.), Little, Brown, and Co., 1982. pp. 745-756.
7. Sikic BI: Antineoplastic agents. In: *Modern Pharmacology*, Craig R and Stitzell R (Eds.), Little, Brown, and Co., 1982, pp. 757-790.
8. Muggia FM, Louie AC and Sikic BI: Pulmonary toxicity of antitumor agents. *Cancer Treat. Rev.* 10: 221-243, 1983.
9. Carlson RW and Sikic BI: Continuous infusion or bolus injection in cancer chemotherapy. *Ann. Intern. Med.* 99: 823-833, 1983.
10. Sikic BI, Chak LY, Daniels JR, Kohler M, and Carter SK: Alternating, non-cross-resistant chemotherapy of small cell lung cancer: a controlled trial from the Northern California Oncology Group. In: *Etoposide (VP-16): Current Status and New Developments*, Carter SK, Muggia F, and Issell BF (Eds.), Academic Press, New York, 1984, pp. 191-198.
11. Sikic BI and Carlson RW: Rate-controlled drug administration in cancer chemotherapy. In: *Rate Control in Drug Therapy*, Prescott LF, Nimmo WS (Eds.), Churchill Livingstone, Edinburgh, 1985, pp. 276-281.
12. Sikic BI: Clinical pharmacology of bleomycin. In: *Bleomycin Chemotherapy*, Sikic BI, Rozenzweig M, and Carter SK, (Eds.) Academic Press, New York, NY, 1985, pp. 37-43.
13. Ballon SC and Sikic BI: Bleomycin in cervical carcinoma: protocols of the Northern California Oncology Group. In: *Bleomycin Chemotherapy*, Sikic BI, Rozenzweig M, and Carter SK, (Eds.) Academic Press, New York, NY, 1985, pp. 239-244.
14. Carlson RW and Sikic BI: Effective treatment of malignant ovarian germ cell tumors with cisplatin, bleomycin and vinblastine (PVB). In: *Bleomycin Chemotherapy*, Sikic BI, Rozenzweig M, and Carter SK, (Eds.) Academic Press, New York, NY, 1985, pp. 69-76.
15. Sikic BI: Pulmonary toxicity of bleomycin. In: *Bleomycin Chemotherapy*, Sikic BI, Rozenzweig M, and Carter SK, (Eds.) Academic Press, New York, NY, 1985, pp. 247-254.

16. Sikic BI and Carlson RW: Effects of schedules of drug administration in cancer chemotherapy. In: *Rate-Controlled Drug Administration and Action*, Struyker-Boudier H (Ed.), CRC Press, Inc., Boca Raton, FL, 1985, pp. 205-219.
17. Sikic BI: The use of new drug delivery systems in clinical pharmacology. In: *Principles and Techniques of Human Research and Therapeutics*, McMahon FG (Ed.), Futura Publishing Co., Mt. Kisco, NY, 1985, pp. 51-62.
18. Sikic BI: The rational basis for cancer chemotherapy. In: *Modern Pharmacology*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, 2nd Edition, 1986, pp.784-796.
19. Sikic BI: Antineoplastic agents. In: *Modern Pharmacology*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, Second Edition, 1986, pp. 797-832.
20. Sikic BI: Antimetabolites and antineoplastics antibiotics. In: *Pharmacologic Aspects of Nursing*, Pagliaro AM and Pagliaro LA (Eds.), C. V. Mosby Co., St. Louis, MO, 1986, pp. 1139-1165.
21. Sikic BI: Alkylating agents and miscellaneous drugs used to treat cancer. In: *Pharmacologic Aspects of Nursing*, Pagliaro AM and Pagliaro LA (Eds.), C. V. Mosby Co., St. Louis, MO, 1986, pp. 1166-1192.
22. Sikic BI: Human tumor clonogenic assays: current status and potential future roles. In: *Fundamentals of Cancer Chemotherapy*, Carter SK and Hellman K (Eds.), McGraw-Hill Book Co., New York, NY, 1986, pp. 425-437.
23. Sikic BI: Theoretical, clinical, and pharmacokinetic aspects of cancer chemotherapy administered by continuous infusion. In: *Clinical Applications of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy*, Rosenthal C and Rotman M, (Eds.), Plenum Publishing Corp., New York, NY, 1986, pp. 3-12.
24. Sikic BI: Anti-cancer drug sensitivity testing: Current role and future prospects. In: *Cancer Chemotherapy: Challenges for the Future*, Kimura K, Yamada K, Krakoff I, and Carter SK, (Eds.), Excerpta Medica, Ltd., Tokyo, 1986, pp. 48-57.
25. Sikic BI: Biochemical and cellular determinants of bleomycin cytotoxicity. *Cancer Surveys* 5: 81-91, 1986.
26. Schein PS, Allegra JC, Glick JH, Livingston RB, Macdonald JS, Sikic BI, and Woolley PV: Oncology Syllabus. In: *Medical Knowledge Self-Assessment Program VII*, American College of Physicians, Philadelphia, PA, 1986, pp. 283-321.
27. Sikic BI: Recent progress in the treatment of seminoma: the article reviewed. *Oncology*, 2: 26-30, 1988.
28. Lau DH, Yong-Sheng Z, and Sikic BI: Drug resistance in cancer chemotherapy. *Shantou Univ. J.*, 3: 113-118, 1988.
29. Sikic BI, Scudder SA, and Evans TL: Multidrug (pleiotropic) resistance in the human sarcoma cell line, MES-SA. In: *Resistance to Antineoplastic Drugs*, Kessel D (Ed.), CRC Press, Boca Raton, FL, 1989, pp. 37-47.
30. Sikic BI: Mechlorethamine. In: *Clinical Cancer Chemotherapy Handbook*, Armand JP, Droz JP, and Khoury S (Eds.), Fondation Internationale pour l'Information Scientifique, Paris, France, 1989, pp. 77-78.
31. Sikic BI: Bleomycin. In: *Clinical Cancer Chemotherapy Handbook*, Armand JP, Droz JP, and Khoury S (Eds.), Fondation Internationale pour l'Information Scientifique, Paris, France, 1989, pp.143-144.
32. Sikic BI: Antitumor antibiotics. *Current Opinion in Oncology*, 1: 198-202, 1989.
33. Sikic BI: The rational basis for cancer chemotherapy. In: *Modern Pharmacology*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, 3rd Edition, 1990, pp.776-786.

34. Sikic BI: Antineoplastic agents. In: *Modern Pharmacology*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, Third Edition, 1990, pp. 787-820.
35. Sikic BI: Combined chemotherapy and radiotherapy for advanced stage carcinomas of the cervix. In: *Radiation/Chemotherapy Interactions in Cancer Therapy*. Meyer JL and Vaeth JM (Eds.), S. Karger AG, Basel, Switzerland, 1992, pp. 153-161.
36. Kühl JS, Sikic BI, Blume KG, and Chao NJ: Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model. In: *Advances in Bone Marrow Purging and Processing*. Worthington-White DA, Gee AP, and Gross S (Eds.), Wiley-Liss, Inc., New York, NY, 1992, pp. 25-34.
37. Lum BL, Gosland MP, Kaubisch S, and Sikic BI: Molecular targets in oncology: implications of the multidrug resistance gene. *Pharmacotherapy* 13: 88-109, 1993.
38. Fisher GA, Brophy NA, Yahanda AM, Adler KA, Lum BL, Bartlett NL, Halsey J, and Sikic BI: The modulation of multidrug resistance: Clinical studies at Stanford. In: *The Mechanism and New Approach on Drug Resistance of Cancer Cells*, Miyazaki T, Takaku F, and Sakurada K (Eds), Excerpta Medica, Amsterdam, 1993, pp 255-266.
39. Leyland-Jones B Dalton W, Fisher GA, and Sikic BI: Reversal of multidrug resistance to cancer chemotherapy. *Cancer* 72: 3484-3488, 1993.
40. Sikic BI: Multidrug resistance and its clinical relevance in acute leukemia: the article reviewed. *Oncology*, 1993
41. Dahl GV, Grier H, Sikic B, Weinstein H, and Arceci R: Multidrug resistance (MDR) reversal utilizing mitoxantrone, etoposide and continuous infusion cyclosporine (MEC) in pediatric ANLL. In: *Acute Leukemias - Prognostic Factors and Treatment Strategies*. Büchner et al. (Eds.) Springer-Verlag, Berlin, 1994, pp. 490-492.
42. Sikic BI: The rational basis for cancer chemotherapy. In: *Modern Pharmacology*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, Fourth Edition, 1994, pp. 663-672.
43. Sikic BI: Antineoplastic agents. In: *Modern Pharmacology*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, Fourth Edition, 1994, pp. 673-703.
44. Sikic BI, Fisher GA, Lum BL, Brophy NA, Yahanda AM, Adler KM, and Halsey J: Clinical reversal of multidrug resistance. In: *Anticancer Drug Resistance: Advances in Molecular and Clinical Research*. Goldstein L and Ozols R (Eds.). Kluwer Academic Publishers, Norwell, MA, 1994, pp. 149-165.
45. Yuen AR and Sikic BI: Multidrug resistance in lymphomas. *J. Clin. Oncol.* 12: 2453-2459, 1994.
46. Fisher GA and Sikic BI: Clinical studies with modulators of multidrug resistance. In: *Drug Resistance in Clinical Oncology and Hematology*. Fisher GA and Sikic BI (Eds.) Hematology/Oncology Clinics of North America, Vol. 9, No. 2. W. B. Saunders Co., Philadelphia, PA, 1995, pp. 363-382.
47. Fisher GA and Sikic BI: Drug resistance in clinical oncology and hematology: Preface. In: *Drug Resistance in Clinical Oncology and Hematology*. Fisher GA and Sikic BI (Eds.) Hematology/Oncology Clinics of North America, Vol. 9, No. 2. W. B. Saunders Co., Philadelphia, PA, 1995, pp. xi-xii.
48. Fisher GA, Lum BL, and Sikic BI: The reversal of multidrug resistance. In: *Concepts, Mechanisms, and New Targets for Chemotherapy*. Muggia FM (Ed.) Kluwer Academic Publishers, Boston, MA, 1995, pp. 45-70.
49. Dahl GV, Brophy N, Grier H, Weinstein H, Sikic B, and Arceci R: Mitoxantrone, etoposide, and cyclosporine A therapy for relapsed and refractory acute myelogenous leukemia, a Pediatric Oncology Group Phase II trial. In: *Acute Leukemias V - Experimental Approaches and Management of Refractory Disease*. Hiddeman W et al. (Eds.) Springer-Verlag, Berlin, 1996, pp.206-209.

50. Fisher GA, Lum BL, Hausdorff J, and Sikic BI: Pharmacological considerations in the modulation of multidrug resistance. *Eur. J. Cancer* 32A: 1082-1088, 1996.
51. Sikic BI: The rational basis for cancer chemotherapy. In: *Modern Pharmacology with Clinical Applications*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, Fifth Edition, 1997, pp. 659-666.
52. Sikic BI: Antineoplastic agents. In: *Modern Pharmacology with Clinical Applications*, Craig CR and Stitzell RE (Eds.), Little, Brown, and Co., Boston, MA, Fifth Edition, 1997, pp. 667-692.
53. Sikic BI: Pharmacologic approaches to reversing multidrug resistance. *Sem. Hematol.* 34 (Suppl.5): 40-47, 1997.
54. Advani R, Saba H, Tallman M, Rowe JM, Wiernik P, Ramek J, Dugan K, Litchman M, Sikic BI, Davis E, Paietta E, and Greenberg P: Treatment of poor prognosis acute myelogenous leukemia with PSC-833 and mitoxantrone, etoposide, cytarabine. In: *Acute Leukemias VII - Experimental Approaches and Management of Refractory Disease*. Hiddeman W et al. (Eds.) Springer-Verlag, Berlin, 1998, pp. 456-460.
55. Dumontet C and Sikic BI: Mechanisms of action of and resistance to anti-tubulin agents: microtubule dynamics, drug transport, and cell death. *J Clin Oncol* 17: 1061-1070, 1999.
56. Sikic BI: New approaches in cancer treatment. *Ann Oncol* 10: S149-S153, 1999.
57. Sikic BI and Berg D: Valspodar. In: *Outline of Oncology Therapeutics*. Ratain MJ, Tempero M, and Skosey C (Eds.). W. B. Saunders Co., Philadelphia, 2001, p. 78.
58. Lacayo NL, Baggott T, and Sikic BI: Pediatric chemotherapy. In: *Problems in Pediatric Drug Therapy*. Pagiario LA and Pagiario AM (Eds), American Pharmaceutical Association. Washington, DC, 2002, pp.493-529.
59. Sikic BI, Sebti SM, and Eckhardt SG: New agents and new targets. In: *American Society of Clinical Oncology 2002 Annual Meeting Summaries*, Johnson DH (Ed.), American Society of Clinical Oncology, Alexandria, VA, 2002, pp. 175-178.
60. Bredel M, Bredel C, and Sikic BI: Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumors? *Lancet Oncol*, 5: 89-100, 2004.
61. Sikic BI: The rational basis for cancer chemotherapy. In: *Modern Pharmacology with Clinical Applications*, Craig CR and Stitzell RE (Eds.), Lippincott, Williams, and Wilkins, Philadelphia, PA, Sixth Edition, 2004, pp. 630-637.
62. Sikic BI: Antineoplastic agents. In: *Modern Pharmacology with Clinical Applications*, Craig CR and Stitzell RE (Eds.), Lippincott, Williams, and Wilkins, Philadelphia, PA, Sixth Edition, 2004, pp. 637-656.
63. Wakelee HA and Sikic BI. Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors. *Clin Lung Cancer*, 7: S6-S12, 2005.
64. Moscow J, Schneider E, Sikic BI, Morrow CS, and Cowan KH: Drug resistance and its clinical circumvention. In: *Holland Frei - Cancer Medicine 7*, Kufe DW, Bast RC, Hait W, Hong WK, Pollock RE, Weichselbaum, RR, Holland JF, and Frei E, Eds., 7th Edition, BC Decker, Publisher, Hamilton, Ontario, Canada, pp. 630-647, 2006.
65. Sikic BI: Natural and acquired resistance to cancer therapies. In: *The Molecular Basis of Cancer* (Mendelsohn JH, Howley PM, Israel MA, Gray J, and Thompson CB Eds.), Third Edition, Elsevier, Philadelphia, PA, pp. 583-592, 2007.
66. Sikic BI: Modulation of classical multidrug resistance and drug resistance in general. In: *Innovative Leukemia and Lymphoma Therapy*, Kaspers GJL, Coiffier B, Heinrich MC, and Estey EH, Eds., Informa Healthcare USA, Inc., New York, NY, 2008.
67. Moscow J, Schneider E, Sikic BI, Morrow CS, and Cowan KH: Drug resistance and its clinical circumvention. In: *Holland Frei - Cancer Medicine 7*, Kufe DW, Bast RC, Hait W, Hong WK,

Pollock RE, Weichselbaum, RR, Holland JF, and Frei E, Eds., 8th Edition, BC Decker, Publisher, Hamilton, Ontario, Canada, Ch. 48, pp. 597-618, 2010.

Editorials and Letters:

1. Sikic BI and Taber RL: Human tumor clonogenic assays - an overview. *Cancer Chemother. Pharmacol.* 6: 201-203, 1981.
2. Sikic BI: Anticancer drug discovery. (Editorial) *J. Natl. Cancer Inst.* 83: 738-740, 1991.
3. Sikic BI: Modulation of multidrug resistance: at the threshold. (Editorial) *J. Clin. Oncol.* 11: 1629-1635, 1993.
4. Dalton WS and Sikic BI: The multidrug resistance gene (*mdr1*) represents a potential target for reversing drug resistance in human malignancies. (Controversies in Science: Multidrug Resistance). *J. NIH Res.* 6: 54-58, 1994.
5. Sikic BI: Modulation of multidrug resistance: a paradigm for translational clinical research. *Oncology* 5A: 183-187, 1999.
6. Sikic BI: Commentary on "Safety and Efficacy of the Multidrug Resistance Inhibitor Incel (Biricodar; VX-710) in Combination with Paclitaxel for Advanced Breast Cancer Refractory to Paclitaxel." *Breast Diseases: a Year Book Quarterly*, 2003.
7. Sikic BI: Combining EGRF inhibitors with chemotherapy. (Editorial). *Signal, the Journal of EGFR-Targeted Cancer Therapy* 5: 2-3, 2004.
8. Sikic BI: Multidrug resistance and stem cells in acute myeloid leukemia. [Editorial]. *Clin Cancer Res*, 12: 3231-2, 2006.
9. Sikic BI, Tibshirani R. and Lacayo NL: Genomics of childhood leukemia: the virtue of complexity. [Editorial]. *J Clin Oncol*, 26: 4367-8, 2008.
10. Sikic BI, Tibshirani R. and Lacayo NL: Reply to Catchpoole et al. [Letter]. *J Clin Oncol*, 28: in press, 2010.

Books:

1. Sikic BI, Rozenzweig M, and Carter SK, (Eds.) Bleomycin Chemotherapy, Academic Press, New York, NY, 1985.
2. Fisher GA and Sikic BI (Guest Eds.) Drug Resistance in Clinical Oncology and Hematology. In: Hematology/Oncology Clinics of North America, Vol. 9, No. 2. W. B. Saunders Co., Philadelphia, PA, 1995.